Rubius makes hard pivot after reviewing clinical data, dumping lead assets and laying off 75% of staffers

Rubius Therapeutics has torn up its strategy. After reviewing human data on its lead candidates, the cell therapy biotech concluded investment in its two clinical prospects “is no longer justified,” leading it to stop studies and lay off 75% of its workforce.